- Stocks
- Pharma & Healthcare
- Everest Organic
Everest Organic share price
NSE: EVERESTOPharma & HealthcareDrug Manufacturers - Specialty & Generic
Everest Organic at a glance
With a market capitalisation of ₹262 Cr, it ranks 2122nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was −1.8% in FY25. Promoters held 59.60% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹262 CrRank 2122 on NSE
- Price to book
- 3.5×FY25
- ROE
- −1.8%FY25
- ROCE
- 2.3%FY25
- Debt to equity
- 0.68FY25
- Net profit margin
- −0.8%FY25
- Book value / share
- ₹72.03FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Everest Organic financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹167 Cr | ₹182 Cr | ₹200 Cr | ₹183 Cr | ₹197 Cr | ₹159 Cr |
| Operating profit | ₹14 Cr | ₹17 Cr | ₹2 Cr | ₹0 Cr | ₹1 Cr | −₹3 Cr |
| Net profit | ₹11 Cr | ₹14 Cr | ₹1 Cr | −₹0 Cr | ₹0 Cr | −₹1 Cr |
| EPS (₹) | ₹13.62 | ₹17.14 | ₹1.43 | −₹0.23 | ₹0.17 | −₹2.97 |
| Cash from operations | ₹10 Cr | ₹14 Cr | ₹14 Cr | ₹18 Cr | ₹16 Cr | −₹5 Cr |
| Total debt | ₹5 Cr | ₹6 Cr | ₹11 Cr | ₹12 Cr | ₹15 Cr | ₹9 Cr |
| Shareholders' equity | ₹34 Cr | ₹47 Cr | ₹47 Cr | ₹46 Cr | ₹46 Cr | ₹70 Cr |
Everest Organic shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 61.09% | 60.78% | 59.64% | 59.61% | 59.58% | 59.60% |
| Domestic institutions | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% |
| Non-institutions | 38.89% | 39.20% | 40.33% | 40.37% | 40.40% | 40.37% |
Everest Organic vs peers
The listed Pharma & Healthcare companies nearest to Everest Organic by market capitalisation.
Ask anything about Everest Organic
Pivot answers on the live chart with evidence you can check, and tests strategies against EVERESTO's own history. Try: “Why has EVERESTO moved over the last three months?” · “Backtest a 50-day moving-average crossover on EVERESTO over five years” · “Compare EVERESTO with ESPIRE on margins and valuation”
Frequently asked questions about Everest Organic
What is the market cap of Everest Organic?
Everest Organic's market capitalisation is ₹262 Cr (₹262 Cr) at the 22 Oct 2026 close, ranking 2122nd among the NSE companies Pivot tracks.
What is the ROE and ROCE of Everest Organic?
Return on equity was −1.8% in FY25 and return on capital employed was 2.3% in FY25 (standalone figures).
Is Everest Organic a debt-free company?
No. Everest Organic's debt-to-equity ratio was 0.68 in FY25, with total debt of ₹9 Cr.
What is the shareholding pattern of Everest Organic?
As of 30 Jun 2026: promoters 59.60%, domestic institutions 0.02%, non-institutions 40.37%.
Who are Everest Organic's competitors?
The listed Pharma & Healthcare companies closest to Everest Organic by market cap are Espire Hospital, Zenotech Labs, Gennex Labs, Kerala Ayur, Nath Bio-Genes (India) and BDH Industries.
Is Everest Organic a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Everest Organic's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on EVERESTO against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with E · all NSE stocks · this page as text